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TELOMERE TESTING
CDKN2A might be better than telomere length in
determining individual health status
Paul G Shiels molecular biologist
Institute of Cancer Sciences, University of Glasgow, Western Infirmary, Glasgow G11 6NT, UK
McCartney notes that telomere length measurement raises more
questions than it answers.1
Determination of personal health status based on a biomarker
of ageing and not as a direct function of chronology requires
very sensitive and specific biomarkers. Validated markers of
biological age are few and must meet the Baker and Sprott
criterion—“A biomarker of ageing is a biological parameter of
an organism that either alone or in somemultivariate composite
will, in the absence of disease, better predict functional
capability at some late age, than will chronological age.”2
Although many biomarkers have been tested, only two fulfil
this criterion—CDKN2A and telomere length. CDKN2A has
been tested only in small independent studies and rarely in
combination with telomere length. In these, telomere length has
proved to be a significantly weaker biomarker. CDKN2A has
also proved to be superior to chronological age.3 4
Inter-individual variation in telomere length is subject to
numerous socioeconomic and lifestyle confounders. This makes
it very unreliable in individuals.5 6 From this standpoint, using
telomere length commercially to determine individual health
status seems premature.
A knowledge of telomere length as a read-out of health is,
however, still very relevant, but only in the context of larger
clinical investigations and population or public health studies,
where socioeconomic, lifestyle, and epigenetic confounders are
taken into account.6 It remains to be determined how relevant
CDKN2A expression will prove to be as a measure of personal
and public health.
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